

RESEARCH ARTICLE

Open Access

Maintenance of cytomegalovirus-specific CD4^{pos} T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments

Jean-Luc Davignon^{*1,2}, Jean-Frédéric Boyer^{1,2}, Bénédicte Jamard², Delphine Nigon^{1,2}, Arnaud Constantin^{2,3} and Alain Cantagrel^{1,2}

Abstract

Introduction: Anti-tumor necrosis factor (TNF)- α biotherapies have considerably changed the treatment of rheumatoid arthritis (RA). However, serious infections are a major concern in patients with rheumatic diseases treated with anti-TNF- α . Little is known about viral, especially latent, infections in anti-TNF- α treatments. Infections by cytomegalovirus (CMV), a β -herpes virus, are frequent and induce a strong CD4^{pos} T-cell immunity, which participates in the control of infection. We thus have chosen to analyze the CD4^{pos} T-cell response to CMV antigens as a model of antiviral response in RA patients treated with anti-TNF- α . CD28 expression was evaluated.

Methods: We have measured the CD4^{pos} response to CMV antigens in RA patients, before and after initiation of treatment with an anti-TNF- α agent. The intracellular production of interferon (IFN)- γ in total and CD28^{neg} CD4^{pos} T cells in response to CMV antigens (Ags) was evaluated with flow cytometry. The proliferation of total CD4^{pos} T cells in the presence of CMV antigens was measured with ³H-thymidine incorporation.

Results: Anti-TNF- α treatments impaired neither the anti-CD4^{pos} anti-CMV IFN- γ response nor the proliferative response in patients. The percentage of CD28^{neg} CD4^{pos} cells remained constant.

Conclusions: Our data suggest that the CD4^{pos} T-cell response against CMV is not altered by anti-TNF- α treatments and that infection remains controlled in treated RA patients latently infected with CMV. Our observation brings new insight into the current knowledge of the risks of infection in patients treated with anti-TNF- α biotherapies.

Introduction

Current therapies for RA are aimed at inhibiting inflammatory cytokines, especially tumor necrosis factor (TNF)- α biotherapies, such as antibodies (infliximab, adalimumab) and soluble receptor (etanercept) specific for TNF. These three commercially available TNF antagonists have been tested in established and in early diseases. They effectively improved disease activity and significantly slowed radiologic deterioration [1,2]. However, serious infections are a major concern in patients with rheumatic diseases, and inhibition of TNF- α increases the risk of serious and benign infections [3]. The role played by TNF- α in the body's defense against bacterial

and viral invasion is multiple: recruitment of neutrophils, eosinophils, and macrophages; release of cytokines and local chemokines; attraction and activation of phagocytes; increased T-cell adhesion; enhanced antigen presentation; and recruitment and proliferation of T and B cells [4]. Moreover, TNF- α is also involved in the formation and sustainment of Mycobacterium granulomatous lesions [5]. Neutralization of TNF- α for treating rheumatic diseases increases the risk of reactivation and outbreak of tuberculosis and other opportunistic infections [6,7]. A decrease of the tuberculosis-specific CD4^{pos} T-cell response in patients treated with anti-TNF was found [8]. In addition, anti-TNF treatment induced a reduction in effector memory CD8^{pos} T cells specific for mycobacteria [9].

In contrast, less is known about viral infections. Herpesviruses can persist in patients in a latent state and be

* Correspondence: jean-luc.davignon@inserm.fr

¹ JE 2510, University Paul Sabatier Toulouse III, France, IFR 150, CPTP, Bâtiment C, CHU Purpan, 1, place Baylac, 31300 Toulouse, France
Full list of author information is available at the end of the article

reactivated under situations of immunosuppression. Although cases of lymphoproliferative disorders have been reported in RA, the role of TNF- α antagonists in Epstein-Barr virus (EBV)-related lymphomas is not clear [3,10,11]. Conversely, inflammation, a hallmark of RA, might be associated with the risk of lymphoma [12]. Regarding EBV infections, data are rather reassuring. In a recent study, no impairment of the anti-EBV CD8^{pos} T-cell response was found in patients treated with anti-TNF, and the EBV viral load was not increased [13]. However, regarding varicella zoster virus, another herpesvirus, a recent publication suggested that anti-TNF- α antibodies could be associated with increased risk of reactivation, responsible for an increased rate of herpes zoster events in patients treated with these biologic agents [14].

Cytomegalovirus (CMV) is a member of the β -herpesvirus subfamily, which infects 50% to 60% of the European population. Primary infections are mostly unnoticed. However, the virus reactivates from latent infections on immunosuppression, leading to graft rejection and severe pathology, such as pneumonitis in bone marrow transplantation, colitis, and retinitis in AIDS [15]. CD4^{pos} and CD8^{pos} T-cell responses against CMV have been studied by using peptides, recombinant proteins, or lysates of infected cells [16-19]. Frequencies of CMV-specific CD4^{pos} and CD8^{pos} T-cells have been shown to be extremely high in immunocompetent persons [17], and to be maintained throughout life [20]. Contributions of CD4^{pos} and CD8^{pos} T cells have been demonstrated both *in vitro* [21,22] and *in vivo*, [23,24].

Although CD4^{pos} T cells possess their own capacity to inhibit CMV replication [21,22,25], they also contribute to the differentiation and maintenance of CMV-specific CD8^{pos} T cells [23]. Moreover, anti-CMV specific effectors are increased in CD28^{neg} CD4^{pos} T cells [17,26], a population that is expanded in RA, because of TNF- α [27,28]. TNF- α has been demonstrated not only to play a prominent role in RA but also to diminish the intensity of the T-cell response [29]. Moreover, anergy of T cells was observed in RA patients [30]. Therefore, the outcome of the anti-CMV CD4^{pos} T-cell response in RA patients treated with anti-TNF- α is of interest.

Case reports have mentioned the reactivation of CMV in anti-TNF-treated patients [3]. It is thus important to know more precisely the persistence of anti-CMV memory CD4^{pos} T cells in RA. The high proportion of CMV-seropositive individuals and the high frequencies of CMV-specific T cells allow the follow-up of the Ag response *ex vivo* [17,18]. We thus have chosen to test the anti-CMV CD4^{pos} T-cell response as a model for the study of the antiviral response in RA patients whose TNF- α is neutralized with anti-TNF. We previously showed that TNF- α participates in the control of infec-

tion [25]. Because neutralization of TNF- α may alter the control of CMV, we thus measured the CD4^{pos} T-cell response in RA patients treated with anti-TNF.

Because IFN- γ produced by CD4^{pos} T cells is important in the control of CMV *in vitro* [25] and *in vivo* [21], we tested the intracellular production of IFN- γ in CD4^{pos} T cells in response to total CMV Ags in patients with RA, before and after initiation of treatment with an anti-TNF- α agent. Specific proliferation in response to CMV Ags also was investigated. Our data show that anti-TNF treatments do not impair the CD4^{pos} anti-CMV response and suggest that CMV infection remains controlled in treated RA patients latently infected with CMV.

Materials and methods

Patients

Patients were included in this study according to several criteria: RA diagnosed according to the 1987 ACR criteria, with active disease, eligible for a first anti-TNF therapy after failure of at least one previous disease-modifying antirheumatic drug (DMARD). Active disease was defined on a Disease Activity Score, assessed by using 28-joint counts (DAS28), above 3.2 [31]. Other associated treatments (DMARD, steroids, NSAIDs) had to be stable for 6 months before inclusion and remain stable during the study.

Patients were tested for CMV serologic status at the time of inclusion. Blood samples were drawn from CMV-seropositive patients before the beginning of anti-TNF- α treatment (day 0) and at weeks 6 and 12 after the beginning of treatment. Blood samples were drawn from CMV-seronegative patients, only once (on day 0) to evaluate the background response of unimmunized subjects.

Patients were receiving either TNF- α soluble receptor (Etanercept) or antibodies (either Infliximab or Adalimumab), according to physicians' choice. Disease Activity Score (DAS 28) was calculated at every visit, and patients' response to treatment was evaluated at week 12 according to EULAR response criteria [32].

The present study was performed with approval of the local ethics committee (CPP Toulouse II), and informed consent was obtained from all participants.

Methods

Separation and preservation of cells

Blood was collected in citrate tubes, and peripheral blood mononuclear cells (PBMCs) were isolated with Lymphoprep gradient separation (Abcys Biology, Paris, France). Cells were then resuspended in 10% DMSO-40% SVF-containing medium and kept frozen in liquid nitrogen.

Antibodies and reagents (preparation of CMV Ag)

Anti-CD4-PE-Cy5 was purchased from eBiosciences (ClniSciences, Montrouge, France), and anti-CD28-PE

and anti-IFN- γ -FITC were purchased from PharMingen (BD PharMingen, Le Pont de Claix, France). Brefeldin A was purchased from Sigma (Sigma-Aldrich, Saint-Quentin Fallavier France).

CMV total Ags were prepared as described in [16]. In brief, MRC5 cells were infected with the Towne strain of CMV at the MOI of 0.1. Cells were harvested 6 days later, washed 3 times in PBS, and lysed by sonication. The sonicate was centrifuged, and the pellet resuspended in PBS, aliquoted, and stored at -80°C . Control Ag was prepared in parallel by using the same protocol, except that cells were uninfected.

Flow cytometry and intracellular IFN- γ assay

Flow cytometry for the detection of intracellular IFN- γ was performed as described by Vaz-Santiago *et al.* [16]. In brief, cells (2×10^6 in 200 μl RPMI medium, 10% SVF) were incubated with the appropriate amount of CMV Ags or control Ags for 4 h. Then Brefeldin A (4 mg/ml) was added for 12 h in 1.6 ml, and cells were left at 37°C under a humidified 5% CO_2 atmosphere. Cells were then washed and stained for surface markers (CD28 and CD4), and then permeabilized by using the Becton Dickinson intracellular cytokine kit. Cells were then stained for intracellular IFN- γ .

Proliferation assay

PBMCs (2×10^5) were incubated in 96-well (200 μl) U-bottomed plates in RPMI-HS (AB CMV seronegative serum) in triplicate, in the presence of either CMV Ags or control Ags. On day 5, cultures were pulsed overnight with [^3H]thymidine ([^3H]TdR; Amersham) (1 μCi /well). The [^3H]TdR incorporation was determined in a beta counter and expressed as the mean of triplicates. The Stimulation Index was calculated as the ratio of means obtained by using CMV Ags over those obtained by using control Ags.

Statistics

After the Shapiro-Francia normality test was applied, the data were analyzed by using nonparametric tests: the Mann-Whitney two-sample statistic, the Kruskal-Wallis (several-sample statistic), and the Wilcoxon matched-pairs signed-ranks test.

Statistical analyses were performed by using Stata Statistical Software (Intercooled Stata 8.2; Stata Corporation, College Station, TX, USA).

Results

Characteristics of patients

Twenty-five patients (23 women and two men) median (extremes) age 55 years (31 to 81 years) years; disease duration, 12 years (2 to 26 years) were included in the present study (Table 1). CMV serologic status was positive in 17 patients but negative in eight patients. All seropositive patients had IgG but no IgM specific for CMV. In

CMV-positive patients, the anti-TNF agent was added to methotrexate in nine, and to leflunomide in one, whereas it was prescribed as monotherapy in seven patients. At week 12, 11 (64.7%) patients were considered good or moderate responders (R), whereas 6 (35.3%) were considered nonresponders (NRs), according to EULAR response criteria. The overall clinical response (64.7%) observed after a 12-week period is in agreement with that reported in other studies [33].

Intracellular IFN- γ response in CD4^{pos} from RA patients treated with anti-TNF

The intracellular CD4^{pos} response was assessed in both CMV-seropositive and -seronegative patients. Figure 1a,b shows the percentage of CD4^{pos} T cells expressing IFN- γ in response to CMV Ags when tested in two patients seropositive for CMV in three consecutive samples (onset of anti-TNF treatment, week 6, and week 12). As expected, the response for CMV Ags was undetectable in seronegative patients (Figure 1c).

The IFN- γ response to CMV Ags (Figure 2a) was detectable in all seropositive patients and was always above that observed in the presence of control Ags (data not shown). The mean percentage of the response to CMV Ags was 0.35%, whereas the response to control Ags was less than 0.02%. No statistical significant modification of the response towards CMV Ags was noted after 6 weeks (0.43%) or 12 weeks (0.49%) of treatment with the TNF blocker. When responders and nonresponders to anti-TNF treatment were compared, no significant difference was observed at any of the time points (data not shown). The same is true when comparing the response to CMV Ags in patients treated with a monoclonal antibody or the soluble receptor of TNF.

Proliferation response to CMV Ags

Proliferation in the presence of CMV Ags was assessed in both CMV-seropositive and -seronegative patients. As expected, seronegative patients did not respond to CMV Ags (data not shown). However, CMV-seropositive patients did respond to CMV Ags, but the response did not significantly vary over the time of exposure to anti-TNF- α (Figure 2b). Similar to what was observed with IFN- γ production, we were not able to find significant patterns in patients classified clinically as responders and nonresponders at week 12 or in patients treated with a monoclonal antibody and those treated with a soluble receptor of TNF.

High percentages of IFN- γ -secreting cells within the CD28^{neg} CD4^{pos} population in response to CMV Ags

It has been reported that the CD28^{neg} population is enriched in RA patients [29] and that this phenotype is due to TNF- α [28,34]. We thus evaluated whether the

Table 1: Characteristics of patients

Patients	RA (years)	Anti-TNF	Steroids	DMARDs	CMV serology status	Clinical response
1	26	ADA	PRED 5	None	+	NR
2	2	ETA	PRED 20	MTX	+	R
3	12	ETA	PRED 5	MTX	+	NR
4	17	INF	None	None	+	R
5	5	ETA	PRED 20	None	+	R
6	4	ETA	PRED 10	None	+	R
7	23	ETA	None	MTX	+	R
8	7	INF	PRED 10	None	+	R
9	26	INF	PRED 7	None	+	R
10	20	ETA	PRED 5	MTX	+	NR
11	14	INF	PRED 10	MTX	+	R
12	20	ADA	PRED 10	MTX	+	R
13	3	ADA	None	Leflunomide	+	R
14	13	INF	PRED 10	None	+	R
15	2	ETA	None	MTX	+	NR
16	12	INF	None	MTX	+	NR
17	12	INF	PRED 10	MTX	+	NR
18	8	INF	None	MTX	-	R
19	17	ETA	PRED 20	MTX	-	R
20	4	INF	None	AlloChryisine	-	R
21	11	ETA	PRED 5	MTX	-	NR
22	15	ETA	None	Leflunomide	-	NR
23	9	ETA	None	MTX	-	R
24	20	ADA	PRED 10	None	-	R
25	13	ADA	None	MTX	-	R

ADA, adalimumab; DMARDs, disease-modifying antirheumatic drugs; ETA, etanercept; INF, infliximab; PRED, prednisone; MTX, methotrexate; NR, nonresponder; R, responder.



clinical status of patients (responder versus nonresponder) would relate to the CD4^{pos} T-cell immunity examined through the CMV-specific CD4^{pos} population. Because the anti-CMV CD4^{pos} T-cell response is enriched in the CD28^{neg} compartment [17,26], we measured the percentage of IFN- γ ^{pos} CD4^{pos} T cells within the CD28^{neg} compartment after exposure to CMV Ags. As expected, Figure 3 shows that the CD4^{pos} T cells specific for IFN- γ ^{pos} were greatly enriched in the CD28^{neg} population (4.7% versus 0.35% in the total CD4^{pos} population), but, again, no significant statistical difference was observed between time points and between responders and nonresponders.



We next evaluated the percentage of total CD28^{neg} among the CD4^{pos} T-cell population during anti-TNF- α treatments (Figure 4). The percentage of CD28^{neg} CD4^{pos}

cells in RA patients was similar to that observed previously by Schmidt *et al.* [27,29]. As previously reported [35], this percentage did not increase over the course of the treatment (6.1%, 6.5%, and 5.2%, respectively, at day 0, week 6, and week 12) (Figure 4). However, contrary to what has been reported [35], no increase of the CD28 intensity was observed in the responders group (data not shown). Although the percentages were higher in the responders population, this difference was not statistically significant at any time point: $P = 0.2278$ at day 0; $P = 0.056$ at week 6; $P = 0.1775$ at week 12.

Discussion

In this work, we analyzed the CD4^{pos} T-cell response to CMV total Ags to evaluate the consequences of treatments with anti-TNF agents on the viral immune mem-





ory response. We observed that the CD4^{pos} T-cell response toward CMV Ags was not altered by anti-TNF antagonists, whether soluble receptor or antibodies.

Production of IFN- γ is a marker and potent effector of the antiviral response, especially against CMV [21,25]. In this work, total CMV Ags were used to monitor the global CD4^{pos} immune response through the IFN- γ production. It appeared that the immunity to viral CMV Ags was conserved during the course of the treatment. Primary infections by CMV are accompanied by the appearance of a high response and frequency of specific CD4^{pos} T cells, which are maintained durably [18,21,36]. The absence of modification of the anti-CMV CD4^{pos} T-cell response in most patients and slight variations in some others observed in our present study are similar to those in previous studies in normal blood donors regarding proliferation [18] and cytokine production by flow cytometry in transplant recipients [37] and HIV patients [36]. Contrary to the anti-mycobacteria CD8^{pos} T-cell response [9], the frequency of anti-CMV CD4^{pos} T cells was not impaired by anti-TNF treatments. Our data suggest that the anti-CMV response is sufficient to control the latent CMV infection during the course of the anti-TNF treatments.

As observed in previous reports [17,26], the percentages of CMV-specific CD4^{pos} T cells in the CD28^{neg} popu-

lation were high, as compared with those observed in the general CD4^{pos} T cell population. We observed that those percentages, obtained by using infected cell lysates, were lower than those observed when using synthetic peptides [17]. However, they were within the range of and in accordance with those reported with whole-cell lysate [17]. Thus, all peptides may not be available as epitopes through processing of total CMV Ags by APC.

The high proportion of CMV-specific CD4^{pos} T cells in the CD28^{neg} population was reported earlier [17,26], but had not been studied in RA. The percentage of CD28^{neg} CD4^{pos} T cells observed in the present study was similar to that observed by Schmidt *et al.* [27] in RA patients.

However, the scope of this present study was not to compare the percentage of CD28^{neg} CD4^{pos} T cells in the normal population and RA patients. We followed the proportion of CD28^{neg} CD4^{pos} T cells during the course of anti-TNF treatment. Despite the neutralization of TNF- α , the percentage of CD28^{neg} CD4^{pos} cells did not vary during the course of anti-TNF treatment in our study. The role of CD28^{neg} CD4^{pos} cells in RA is not elucidated, but it has been suggested that they do not play an aggressive role in autoimmunity and may not play a specific role in RA [34].

Hyporesponsiveness was reported in RA patients in T cells from synovial fluid [30]. The significant response of CD4^{pos} T cells from peripheral blood at day 0 of treat-

ment and the relatively stable anti-CMV response over the course of treatment in our current study suggest (a) that anergy to anti-CMV Ags, if any, was not a prominent feature of RA patients; and (b) that anti-TNF treatments did not restore function from CD4^{pos} T cells putatively engaged in anergy or in TNF- α -induced hyporesponsiveness [29].

Several studies have analyzed the *in vitro* responses to pathogens that are at risk in RA patients treated with anti-TNF. The *ex vivo* anti-mycobacteria IFN- γ response was found to be impaired by infliximab and adalimumab [8] and was in accordance with the risk of reactivation of tuberculosis, especially with antibodies [38]. The situation regarding the antiviral immunity may be more complex and has been less explored. Although HBV has been described to reactivate on anti-TNF treatment [3], long-term safety of TNF blockers requires longer follow-up regarding HCV [3,39].

Regarding EBV, a member of the herpes family, the risk of lymphoma has been debated [3]. The anti-EBV response was found to be maintained [13], suggesting that no short-term (3 month) defect in EBV-immune surveillance occurs in patients receiving MTX or anti-TNF drugs.

A risk of varicella-zoster virus infection, another member of the herpes virus family, may be present, as reported by Strangfeld *et al.* [14]. However, *in vitro* studies of the CD4^{pos} T-cell response against varicella-zoster Ags have not been performed. Several cases of CMV infection have been reported during the course of anti-TNF treatments [3,40,41]. However, because patients received concomitant immunosuppressive treatments, it is difficult to establish a link between anti-TNF treatment and reactivation of CMV.

Our present data argue in favor of the maintenance of anti-CMV immunity during anti-TNF treatments. This is of importance in light of previous observations that TNF- α is an important component of the anti-CMV control *in vitro* [25,42]. Our current study and former published reports [8,13] suggest that *in vitro* responses to viral proteins or peptides are of help to identify risks of viral infection in patients treated with anti-TNF. In addition, the conservation of anti-CMV CD4^{pos} T cell immunity during anti-TNF treatment suggests that vaccinations can be envisaged during treatment by anti-TNF. However, until safety data are available, live attenuated virus vaccines should be contraindicated in RA patients.

Conclusions

We have used the anti-CMV CD4^{pos} T-cell response as a test for the integrity of the antiviral immune response during anti-TNF treatments. Our data show that the anti-CMV CD4^{pos} T-cell IFN- γ and proliferative responses are maintained during anti-TNF treatments. No modifica-

tion of the percentage of specific or total CD28^{neg} CD4^{pos} T cells during anti-TNF treatments was observed. Because CD4^{pos} T cells are an important component of the anti-CMV immunity, our observations suggest that CMV infections are well controlled during anti-TNF treatments and bring new insight into the current knowledge of the risks of infection in patients treated with anti-TNF- α biotherapies.

Abbreviations

Ags: antigens; CMV: cytomegalovirus; RA: rheumatoid arthritis.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

J-LD, ACo, and ACa designed the study. DN participated in the design of the study and performed the statistical analysis. J-LD and J-FB performed the experiments. J-FB, BJ, ACo, and ACa enrolled patients. J-LD, ACo, and ACa wrote the manuscript. All authors helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by Société Française de Rhumatologie and University Paul Sabatier Toulouse III. We thank Michel Baron for excellent technical assistance. We thank the flow-cytometry facilities (Dr. F-E L'Faqihi-Olive of IFR150 (Toulouse, France) and M.-H. Cerato) for help with the collection of data.

Author Details

¹JE 2510, University Paul Sabatier Toulouse III, France, IFR 150, CPTP, Bâtiment C, CHU Purpan, 1, place Baylac, 31300 Toulouse, France, ²Centre of Rheumatology, CHU Purpan, 1, place Baylac, BP 3028, 31024 Toulouse, France and ³INSERM U558, Toulouse, Faculté de Médecine, 37, allées Jules Guesde, 31073 Toulouse Cedex, France

Received: 16 March 2010 Revised: 26 May 2010

Accepted: 15 July 2010 Published: 15 July 2010

References

1. Ruderman EM: **Current and future pharmaceutical therapy for rheumatoid arthritis.** *Curr Pharm Des* 2005, **11**:671-684.
2. Smolen JS, Steiner G: **Therapeutic strategies for rheumatoid arthritis.** *Nat Rev Drug Discov* 2003, **2**:473-488.
3. Domm S, Cinatl J, Mrowietz U: **The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature.** *Br J Dermatol* 2008, **159**:1217-1228.
4. Camussi G, Albano E, Tetta C, Bussolino F: **The molecular action of tumor necrosis factor-alpha.** *Eur J Biochem* 1991, **202**:3-14.
5. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P: **The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection.** *Cell* 1989, **56**:731-740.
6. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD: **Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.** *Arthritis Rheum* 2003, **48**:2122-2127.
7. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwietzman WD, Siegel JN, Braun MM: **Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.** *N Engl J Med* 2001, **345**:1098-1104.
8. Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, Baron G, Lemann M, Puechal X, Breban M, Berenbaum F, Delchier JC, Flipo RM, Dautzenberg B, Salmon D, Humbert M, Emilie D: **Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists.** *Arthritis Res Ther* 2006, **8**:R114.
9. Bruns H, Meinken C, Schauenberg P, Harter G, Kern P, Modlin RL, Antoni C, Stenger S: **Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against *Mycobacterium tuberculosis* in humans.** *J Clin Invest* 2009, **119**:1167-1177.

10. Wolfe F, Michaud K: **Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.** *Arthritis Rheum* 2004, **50**:1740-1751.
11. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LT: **Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.** *Ann Rheum Dis* 2005, **64**:699-703.
12. Baecklund E, Iliadou A, Askling J, Ekblom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundstrom C, Klareskog L: **Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.** *Arthritis Rheum* 2006, **54**:692-701.
13. Miceli-Richard C, Gestermann N, Amiel C, Sellam J, Ittah M, Pavy S, Urrutia A, Girault I, Carcelain G, Venet A, Mariette X: **Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies.** *Arthritis Res Ther* 2009, **11**:R77.
14. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A: **Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.** *JAMA* 2009, **301**:737-744.
15. Sissons JG, Carmichael AJ, McKinney N, Sinclair JH, Wills MR: **Human cytomegalovirus and immunopathology.** *Springer Semin Immunopathol* 2002, **24**:169-185.
16. Vaz-Santiago J, Lule J, Rohrlch P, Jacquier C, Gibert N, Le Roy E, Betbeder D, Davignon JL, Davrinche C: **Ex vivo stimulation and expansion of both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65.** *J Virol* 2001, **75**:7840-7847.
17. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, Nelson JA, Picker LJ: **Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects.** *J Exp Med* 2005, **202**:673-685.
18. Davignon JL, Clement D, Alriquet J, Michelson S, Davrinche C: **Analysis of the proliferative T cell response to human cytomegalovirus major immediate-early protein (IE1): phenotype, frequency and variability.** *Scand J Immunol* 1995, **41**:247-255.
19. Prieur E, Betbeder D, Niedergang F, Major M, Alcover A, Davignon JL, Davrinche C: **Combination of human cytomegalovirus recombinant immediate-early protein (IE1) with 80 nm cationic biovectors: protection from proteolysis and potentiation of presentation to CD4+ T-cell clones in vitro.** *Vaccine* 1996, **14**:511-520.
20. Vescovini R, Biasini C, Fagnoni FF, Telera AR, Zanlari L, Pedrazzoni M, Bucci L, Monti D, Medici MC, Chezzi C, Franceschi C, Sansoni P: **Massive load of functional effector CD4+ and CD8+ T cells against cytomegalovirus in very old subjects.** *J Immunol* 2007, **179**:4283-4291.
21. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ: **Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease.** *Blood* 2003, **101**:2686-2692.
22. Le Roy E, Baron M, Faigle W, Clement D, Lewinsohn DM, Streblow DN, Nelson JA, Amigorena S, Davignon JL: **Infection of APC by human cytomegalovirus controlled through recognition of endogenous nuclear immediate early protein 1 by specific CD4(+) T lymphocytes.** *J Immunol* 2002, **169**:1293-1301.
23. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR: **Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.** *N Engl J Med* 1995, **333**:1038-1044.
24. Einsele H, Roosnek E, Ruffer N, Sinzger C, Riegler S, Loffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L, Kleihauer A, Frank F, Jahn G, Hebart H: **Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy.** *Blood* 2002, **99**:3916-3922.
25. Davignon JL, Castanie P, Yorke JA, Gautier N, Clement D, Davrinche C: **Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro.** *J Virol* 1996, **70**:2162-2169.
26. Amyes E, Hatton C, Montamat-Sicotte D, Gudgeon N, Rickinson AB, McMichael AJ, Callan MF: **Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection.** *J Exp Med* 2003, **198**:903-911.
27. Schmidt D, Goronzy JJ, Weyand CM: **CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity.** *J Clin Invest* 1996, **97**:2027-2037.
28. Bryl E, Vallejo AN, Weyand CM, Goronzy JJ: **Down-regulation of CD28 expression by TNF-alpha.** *J Immunol* 2001, **167**:3231-3238.
29. Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Brennan FM, Maini RN, Feldmann M: **Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis.** *J Clin Invest* 1994, **94**:749-760.
30. Romagnoli P, Strahan D, Pelosi M, Cantagrel A, van Meerwijk JP: **A potential role for protein tyrosine kinase p56(lck) in rheumatoid arthritis synovial fluid T lymphocyte hyporesponsiveness.** *Int Immunol* 2001, **13**:305-312.
31. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL: **Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.** *Arthritis Rheum* 1995, **38**:44-48.
32. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL: **Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.** *Arthritis Rheum* 1996, **39**:34-40.
33. Choy EH, Smith C, Dore CJ, Scott DL: **A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.** *Rheumatology (Oxford)* 2005, **44**:1414-1421.
34. Thewissen M, Somers V, Hellings N, Fraussen J, Damoiseaux J, Stinissen P: **CD4+CD28null T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulation.** *J Immunol* 2007, **179**:6514-6523.
35. Bryl E, Vallejo AN, Matteson EL, Witkowski JM, Weyand CM, Goronzy JJ: **Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis.** *Arthritis Rheum* 2005, **52**:2996-3003.
36. Komanduri KV, Donahoe SM, Moretto WJ, Schmidt DK, Gillespie G, Ogg GS, Roederer M, Nixon DF, McCune JM: **Direct measurement of CD4+ and CD8+ T-cell responses to CMV in HIV-1-infected subjects.** *Virology* 2001, **279**:459-470.
37. Widmann T, Sester U, Gartner BC, Schubert J, Pfreundschuh M, Kohler H, Sester M: **Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation.** *PLoS One* 2008, **3**:e3634.
38. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lorthololary O, Mariette X: **Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry.** *Arthritis Rheum* 2009, **60**:1884-1894.
39. Nathan DM, Angus PW, Gibson PR: **Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach.** *J Gastroenterol Hepatol* 2006, **21**:1366-1371.
40. Helbling D, Breitbach TH, Krause M: **Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy.** *Eur J Gastroenterol Hepatol* 2002, **14**:1393-1395.
41. Mizuta M, Schuster MG: **Cytomegalovirus hepatitis associated with use of anti-tumor necrosis factor-alpha antibody.** *Clin Infect Dis* 2005, **40**:1071-1072.
42. Allan-Yorke J, Record M, de Preval C, Davrinche C, Davignon JL: **Distinct pathways for tumor necrosis factor alpha and ceramides in human cytomegalovirus infection.** *J Virol* 1998, **72**:2316-2322.

doi: 10.1186/ar3083

Cite this article as: Davignon et al., Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments *Arthritis Research & Therapy* 2010, **12**:R142